Avadel Pharmaceuticals PLC

Alkermes plc has completed its acquisition of Avadel Pharmaceuticals plc, integrating LUMRYZ and a commercial team to accelerate its entry into the sleep medicine market.

The High Court of Ireland has scheduled a hearing for February 10, 2026, to sanction the proposed acquisition of Avadel Pharmaceuticals by Alkermes plc.

Avadel Pharmaceuticals plc shareholders overwhelmingly approved the proposed acquisition by Alkermes plc at special meetings held on January 12, 2026.

Avadel Pharmaceuticals announced the completion of patient enrollment in its Phase 3 REVITALYZ trial for LUMRYZ in idiopathic hypersomnia, with data expected in Q2 2026.

The waiting period under the Hart-Scott-Rodino Act has expired for Alkermes' acquisition of Avadel Pharmaceuticals, satisfying a key closing condition.

Alkermes plc has increased its offer to acquire Avadel Pharmaceuticals plc to up to $22.50 per share, including a superior contingent value right, following a competing proposal.

Avadel Pharmaceuticals reports significant revenue growth and profitability, driven by LUMRYZ sales, and announces its acquisition by Alkermes plc for $18.50 cash plus a $1.50 CVR per share.

Avadel Pharmaceuticals PLC reported significant revenue and profit growth in Q2 2025, driven by increasing patient uptake of its narcolepsy drug LUMRYZ, alongside key regulatory and legal victories.

Avadel Pharmaceuticals' Q1 2025 net product revenue surged to $52.5 million, a 93.2% increase year-over-year, primarily driven by the continued commercialization of LUMRYZ.

Avadel Pharmaceuticals saw a significant increase in revenue during the third quarter of 2024, primarily driven by sales of its narcolepsy drug, LUMRYZ.

Avadel Pharmaceuticals saw a significant increase in revenue in the second quarter of 2024, primarily driven by sales of its narcolepsy drug, LUMRYZ.

Avadel Pharmaceuticals reported a net product revenue of $27.2 million for the first quarter of 2024, primarily driven by sales of its narcolepsy drug, LUMRYZ.

Avadel Pharmaceuticals' 10-K filing summarizes the company's financial performance for 2024, focusing on the commercialization of LUMRYZ and its future prospects.

Avadel Pharmaceuticals has filed an amendment to its 2023 annual report to include previously omitted information regarding directors, executive officers, and corporate governance.

Avadel Pharmaceuticals details its share capital, including ordinary and preferred shares, and outlines key corporate governance provisions in a recent SEC filing.

Avadel Pharmaceuticals' Chief Operating Officer, Susan Rodriguez, disposed of 300,000 stock options as part of the company's acquisition by Alkermes plc.

Avadel Pharmaceuticals plc director Peter J. Thornton reports the disposition of all shares and options following the company's acquisition by Alkermes plc for $21.00 cash plus a contingent value right per share.

Avadel Pharmaceuticals General Counsel Jerad Seurer disposed of ordinary shares and stock options following the company's acquisition by Alkermes plc.

Avadel Pharmaceuticals plc shareholders receive $21.00 cash and a $1.50 CVR per share as Alkermes plc completes its acquisition.

Avadel Pharmaceuticals CFO Thomas S. McHugh disposed of all ordinary shares and stock options following the company's acquisition by Alkermes plc for $21.00 cash plus a contingent value right per share.

Avadel Pharmaceuticals director Mark Anthony McCamish disposed of all his direct and indirect ordinary shares and stock options as part of Alkermes plc's acquisition of Avadel.

Alkermes CEO Richard Pops sent a message to Avadel Pharmaceuticals employees, expressing excitement for the upcoming acquisition and integration, and outlining future plans.

Avadel Pharmaceuticals announced the expiration of the HSR Act waiting period, satisfying a key condition for its acquisition by Alkermes.

Avadel Pharmaceuticals shareholders are invited to vote on Alkermes' proposed acquisition for $21.00 cash plus a $1.50 CVR per share, valuing the company at up to $2.37 billion.

Avadel Pharmaceuticals and Alkermes plc have amended their acquisition agreement, increasing the offer to up to $22.50 per share, with Avadel's Board reaffirming its recommendation for Alkermes.

Alkermes plc has increased its recommended offer to acquire Avadel Pharmaceuticals plc to up to $22.50 per share, a move prompted by a competing proposal from H. Lundbeck A/S.

Avadel Pharmaceuticals' Board of Directors has determined that H. Lundbeck A/S's unsolicited acquisition proposal, valued at up to $23.00 per share, constitutes a Company Superior Proposal compared to its existing agreement with Alkermes.

Janus Henderson Group plc reported a 1.9% beneficial ownership stake in Avadel Pharmaceuticals PLC, holding 1,823,865 ordinary shares as of December 31, 2025.

Brandes Investment Partners, L.P. reported a 0.22% passive stake in Avadel Pharmaceuticals PLC, holding 218,835 common shares.

Tontine Asset Associates, Tontine Capital Overseas Master Fund II, and Jeffrey L. Gendell have filed an exit Schedule 13G/A, reporting their beneficial ownership in Avadel Pharmaceuticals plc has fallen below 5%.

Janus Henderson Group plc has reported an increased beneficial ownership of 7.7% in Avadel Pharmaceuticals PLC's common stock, holding 7,429,718 shares.

Janus Henderson Group plc has increased its beneficial ownership in Avadel Pharmaceuticals PLC to 11.5% of common stock, holding 11,132,131 shares as of June 30, 2025.

Two Seas Capital LP, along with its general partner and chief investment officer, reported a 6.4% beneficial ownership stake in Avadel Pharmaceuticals plc.